FLT3 and acute myeloid leukemia: In a multivariable Cox model accounting for the established prognostic parameters age, cytogenetic risk, NPM1 and FLT3-ITD mutation status, lactate dehydrogenase (LDH), white blood cell (WBC) and secondary AML, treatment with sorafenib retained its significant influence on EFS with an adjusted HR of 0.61 (95% CI 0.44–0.87; p = 0.006).